Posted 8/19/2014 7:22 PM (GMT 0)
Thanks, everyone, for your interest and especially to those of you who gave well-reasoned responses from the heart in the true spirit of this site…to help others. As I mentioned at the very opening of this thread, and in the spirit of a tread A Yooper started shortly before this one about advanced imaging, we CAN help newcomers by sharing knowledge. Before proceeding, a few quotes to ponder on sharing knowledge…your comment is welcomed if any of these resonate with you; if, however, the very idea of rationally discussing PC overtreatment fills you with “sound and fury,” as it apparently does for some people, you are most welcomed to post elsewhere (or else I’ll say “thanks,” in advance, again, to the mods for intervening):
Leonardo da Vinci: “Where there is shouting, there is no true knowledge.”
Carlos Castaneda: “A man of knowledge lives by acting, not by thinking about acting.”
Stokely Carmichael: “The knowledge I have now is not the knowledge I had then.”
Margaret Fuller: “If you have knowledge, let others light their candles in it.”
I was pleased to see that the numbered lines of the original posting raised very little controversy…I'll take that as a positive confirmation. I’d like to add a few replies to some of the thoughtful comments which have been made in the thread…
medved added a comment about men “electing” to be overtreated (compiler also made a similar comment later). I did already reply in essence that, indeed, any favorable-risk case is counted amongst the 1-2 million cases of PC overtreatment whether they “elected” treatment, or they were forced at gunpoint to undergo treatment [please forgive my use of hyperbole/exaggeration I this instance, it is merely to make this point]. But medved commented further about the “need” to be treated [his words here] “ not from a (pure) urology point of view, but from a psychology point of view .”
In reply to medved, it may be best to reuse the words of others rather than my own words. Faina Shtern, CEO of a nonprofit group which has been lobbying Congress to increase federal funding for research into prostate imaging recently addressed medved’s point: “ Right now we are treating people for anxiety, not cancer .” AS is not for every case [more discussion on this point later], but it is underutilized today for the pool of men for whom it would be the most appropriate solution. This is shifting with growing awareness, and will continue shifting, but it will not shift overnight...and there will always be a percentage of men who "treat the name (cancer) rather than treat the disease."
RCS, thanks for your value-added comments. As noted, I did make a correction based on your attentive input.
Purgatory, your suggestion that “ AS should be the only insurance paid option ” for favorable-risk cases might be an idea-before-it’s-time…similar to the Clinton Healthcare plan of 1993 which proposed comprehensive, universal health care for all Americans. It wasn’t “ready for primetime” in 1993, but twenty years later a large number of American opinions have shifted. Now, let’s not get political—I’m not!—this is just an illustrative example of another idea, like Purgatory’s, which may not be “ready for primetime” just yet. Others, like clocknut, also posted later in the thread an opposition to “enforced” AS for favorable-risk patients by drawing upon the parallelism of women’s “right to choose.”
However, to quote from a “New” Prostate Cancer “Infolink” summary of two articles on the economic burden of our existing “management strategies” for favorable-risk PC, “ The high and increasing prevalence of PC detection is placing a significant economic burden on society. The truth is that such continued costs are not sustainable, and we need to implement better management strategies and more cost-efficient processes to lower the burden on society of PC management. If we don't find ways to do this, it will just become one more of the many straws that finally break the back of the growing global health care budget .”
In another article, Dr Fisher echoed this perspective (this article was specifically about the treatment of favorable-risk patients by proton beam therapy, which it coined as “ the most expensive medical device in the history of the world ” ). The article says that Americans devote more of their paychecks to health care than workers in any other country worldwide, yet have a life expectancy that ranks 49th, just behind Portugal. Estimates vary widely, but studies suggest that a large portion of the steady rise in health-care costs can be attributed to new technologies. "If we continue at this pace, health care will be unaffordable for our children."
Purgatory, I do also believe (as I believe you are saying) that something has to change…and if it doesn’t change from the bottoms-up, there will need to be a top-down change which may be as dramatic as you propose. We’ll see.
MsWorryWart, I recognized your humor immediately…and while I hate explaining jokes, the lobotomy is certainly an alternative to treat the psychological issues mentioned…very good. While in jest, good point.
toyoung commented [I am paraphrasing] about how new imaging techniques (and other testing) are coming close to eliminating remaining questions about favorable-risk cases. He also mentioned how his original urologist who diagnosed him (only 2 years ago, with a single core of 3+3 PC) did not recommend these tests for him, and recommended him for surgery. [I’ll add that his two subsequent biopsies have both been negative, and that he’s on an AS program at MSK.]
Understaging is a concern expressed here and related to toyoung’s comment (also commented on by both PeterDisAbelard and compiler) and in other threads, but with this decade’s advancement in imaging techniques, that concern has largely disappeared from contemporary language of up-to-date physicians . It is well acknowledged that in confirmatory, follow-up biopsies in studies performed a decade or more ago on men with 3+3 PC, about 50% stayed at 3+3 while about 50% were either upstaged or downstaged; roughly 25% each. Similarly, post-surgical pathology re-confirmed this finding with somewhere around a quarter to a third of 3+3 patients being upstaged, almost exclusively (but not exclusively) to 3+4 (so-called “ adverse pathology ”). Sample biopsies are NOT perfect in what they find…but the important point is that being upstaged from 3+3 to 3+4 is not likely an issue at all. The fact is that most of the leading AS programs are now including favorable-risk 3+4 patients in their programs…and they appear to be doing fine. [I did already mention the additional fact that a very small percentage of cases which initially appear to be low-risk do become life threatening, but these occur at about the same rates whether one has immediate, aggressive treatment OR NOT .]
I’d like to share several other comments on this topic…but rather than use only my words, out of deference to PDA’s treatise on opinions & buses, which I understand to have been directed elsewhere, I’ll call, first, Dr Peter Scardino to the podium. [Dr Scardino is a cancer surgeon (Department of Surgery Chairman) and researcher at MSK, and author expert in genitourinary and urological cancers, particularly cancer of the prostate.] Nearly 5-years ago , Dr Scardino wrote that " Understaging/grading can be essentially eliminated with repeat biopsies and MRI and careful monitoring, making AS safe and acceptable ." The purpose of MRI isn’t to see small cancers, just to see if a big cancer was missed.
And now for another comment from a recognized PC expert, Dr Peter Carroll . [Dr Carroll (like Dr Scardino, also a surgeon) is an expert in managing urologic cancers at UC-San Francisco. He is co-director of the UCSF Urologic Cancer Center, and chairman of the Department of Urology.] Dr Carroll wrote in an editorial: “ AS patients, if well selected and monitored, do not appear to sacrifice the ability to be effectively treated at a later date. ... Clinicians and patients considering active surveillance should understand that under grading and under staging could occur and that the disease could be of a higher grade and volume. However, such risks are minimized with the use of a well performed extended pattern prostate biopsy, an essential component of initial and ongoing risk assessment, and other advanced imaging techniques. Under staging and significant under grading are not the problems today that they were 2 decades ago .”
Also, A Yooper’s earlier thread which included Dr Mark Scholz’s blog comments on MP-MRI imaging as a means to reduce PC overtreatment is a good read .
Scardino, Carroll and Scholz are amongst the very top-of-the-top in prostate cancer care. They’ve got some of the best and most up-to-date opinions give heed to.
hrpufnstuff commented: “ I'm surprised to see that the NCCN guidelines for low risk don't mention getting further testing to confirm the low risk diagnosis .”
I would simply say that the NCCN Prostate Cancer Guidelines are comprehensive in that they address the full, broad range of possible PC treatments, but they do not necessarily go into complete depth with each and every one of those treatment modes. The document is wide, but not deep. For more on any one of those modes, one would look elsewhere. For example, on the other end of the spectrum of the disease, you will not find everything one would want to know about ADT in the NCCN Guidelines…only descript ion of when ADT is appropriate treatment. I hope that this addresses your “ surprise .”
Ziggy9 commented on the psyche of a patient possibly looking back at his own case of possibly being overtreated. I won’t comment further on this. “Treatment regret” may exist for some people, but we’re not about looking in the rear view mirror…I’m more about looking forward to the next favorable-risk newcomer coming through the doorway with a look of terror from hearing the “big ‘C’” and not knowing what to do. We can help that guy. That guy, I believe, represents the most under-supported subset of men diagnosed with PC today.
And lastly, another of Ziggy9’s comments links directly to another point that bears repeating, again…and again-and-again if necessary. None of this talk about overtreatment or AS applies to men diagnosed with higher-grade PC. It simply is not applicable. It never ceases to amaze me when, despite this clear statement, confusion about this still occasionally pops-up.
edit: fixed a few typos Post Edited (JackH) : 8/19/2014 1:40:57 PM (GMT-6)